Skip to main content
Year archive

Egetis Therapeutics — 2026 filings

All 19 regulatory filings released by Egetis Therapeutics (EGTX) in 2026, sourced directly from the official regulator.

19 Filings
2026 Period
2026 filings (19)
Filing Released Lang
Ändring av antalet aktier och röster i Egetis Therapeutics
Regulatory Filings
2026-04-30 English
Change in the number of shares and votes in Egetis Therapeutics
Regulatory Filings
2026-04-30 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Q1 2026
2026-04-29 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Q1 2026
2026-04-29 English
Egetis Therapeutics har framgångsrikt genomfört en riktad nyemission uppgående till 350 miljoner kronor (cirka 38 miljoner dollar)
Share Issue/Capital Change
2026-04-21 Swedish
Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million)
Share Issue/Capital Change
2026-04-21 English
Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million)
Share Issue/Capital Change
2026-04-21 English
Egetis Therapeutics offentliggör avsikten att genomföra en riktad nyemission om cirka 350 miljoner kronor (cirka 38 miljoner dollar)
Share Issue/Capital Change
2026-04-21 Swedish
Kommuniké från Egetis Therapeutics årsstämma 2026
Declaration of Voting Results & Voting Rights Announcements
2026-04-14 Swedish
Bulletin from Egetis Therapeutics’ Annual General Meeting 2026
Declaration of Voting Results & Voting Rights Announcements
2026-04-14 English
Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency
Regulatory Filings
2026-03-27 English
Egetis meddelar att FDA accepterar och beviljar prioriterad granskning av NDA för Emcitate® (tiratricol) vid MCT8 brist
Regulatory Filings
2026-03-27 Swedish
Annual Report (ESEF) 2025
Annual Report (ESEF) FY 2025
2026-03-24 Swedish
KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB (PUBL)
Proxy Solicitation & Information Statement
2026-03-12 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)
Proxy Solicitation & Information Statement
2026-03-12 English
Earnings Release 2025
Earnings Release FY 2025
2026-02-26 Swedish
Audit Report / Information 2025
Audit Report / Information FY 2025
2026-02-26 English
Egetis slutför rullande ansökan om marknadsgodkännande (NDA) i USA för Emcitate® (tiratricol) för behandling av MCT8-brist
Regulatory Filings
2026-01-29 Swedish
Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency
Regulatory Filings
2026-01-29 English